TOP NEWS

Amgen Acquires Ilypsa For $420M

Thousand Oaks-based Amgen announced Monday afternoon that it has agreed to acquire Santa Clara-based Ilypsa, a company developing non-absorbed drugs for renal disorders. The deal is worth $420M in cash. Ilypsa's compounds are targeted at treating kidney disease and its complications. The firm's compound has completed Phase 2 studies for the treatment of hyperphosphatemia in chronic kidney disease (CKD) patients on hemodialysis. The acquisition of Ilypsa is expected to close in the third quarter of 2007.


LATEST HEADLINES

More Headlines

BROWSE ISSUES